ReShape Total Stockholder Equity from 2010 to 2024
| RSLS Stock | USD 0.25 0.03 10.71% |
Total Stockholder Equity | First Reported 2005-12-31 | Previous Quarter 6.7 M | Current Value 6.7 M | Quarterly Volatility 18.3 M |
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape main balance sheet or income statement drivers, such as Interest Expense of 24.7 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many exotic indicators such as Price To Sales Ratio of 0.16, Dividend Yield of 0.0 or PTB Ratio of 0.21. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
ReShape | Total Stockholder Equity |
Latest ReShape Lifesciences' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of ReShape Lifesciences over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. ReShape Lifesciences' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
ReShape Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 17,903,346 | |
| Coefficient Of Variation | 114.30 | |
| Mean Deviation | 14,497,548 | |
| Median | 11,875,000 | |
| Standard Deviation | 20,464,413 | |
| Sample Variance | 418.8T | |
| Range | 77M | |
| R-Value | 0.11 | |
| Mean Square Error | 445.1T | |
| R-Squared | 0.01 | |
| Significance | 0.69 | |
| Slope | 522,482 | |
| Total Sum of Squares | 5863.1T |
ReShape Total Stockholder Equity History
About ReShape Lifesciences Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ReShape Lifesciences income statement, its balance sheet, and the statement of cash flows. ReShape Lifesciences investors use historical funamental indicators, such as ReShape Lifesciences's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may use each financial statement separately, they are all related. The changes in ReShape Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ReShape Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ReShape Lifesciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ReShape Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 6.7 M | 6.3 M |
Pair Trading with ReShape Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving against ReShape Stock
| 0.53 | WST | West Pharmaceutical | PairCorr |
| 0.44 | SSY | SunLink Health Systems | PairCorr |
| 0.43 | FNA | Paragon 28 | PairCorr |
| 0.41 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.
The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of ReShape Lifesciences Correlation against competitors. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.732 | Quarterly Revenue Growth (0.15) | Return On Assets (0.57) | Return On Equity (1.78) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.